Fundraising Fox
Dignify Therapeutics
Research Triangle Park, US · Founded 2013 · Delaware LLC · 3 known investors
Find your way into Dignify Therapeutics
Sign up to see every warm intro you have to Dignify Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dignify Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dignify Therapeutics is developing drug programs that induce on-demand defecation and urination to treat functional bowel and bladder disorders, including incontinence and retention associated with neurological conditions and aging. Its candidates are intended to reduce reliance on bladder catheters, manual bowel programs, and adult wearables, and to lower the risk of related infections and hospitalization.
Founders & leadership
Dignify Therapeutics was founded in 2013 by Edward C Burgard and Karl Thor.
EC
Edward C BurgardCo-founder
BW
Benny WardChief Executive Officer, Co-Founder and Board Member2014–2017Benny Ward is an executive with experience spanning pharmaceutical and medical device companies at various stages, including serving as CEO of an early-stage venture-backed pharmaceutical development company, EVP of business development at a public specialty pharmaceutical firm, and leadership roles in device companies through IPO and acquisition.
AD
Anthony DiTonnoCEO
EB
Ed BurgardPresident
JW
Jeff WelchChief Operating Officer
LM
Lesley MarsonVP of Preclinical Research
DR
Dan RiccaVP of Chemistry
MA
Mary A KatofiascDirector of Operations
Board
FE
HP
Howard PalefskyBoard director
DJ
Daniel J RiccaBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$4.2M disclosed across 2 rounds · 2014–2026
▶$800KraisedSep 2026 · 2 investors · PharmaceuticalsRule 506(b)
▶$800KraisedSep 2026 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anthony DiTonnoExecutive Officer, Director
- Edward C. BurgardDirector
- Eric GreenDirector
- Karl B. ThorDirector
- Neil KurtzDirector
- Howard PalefskyDirector
- Offering amount
- $3M
- Amount sold
- $800K
- First sale
- Sep 2026
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedFeb 2015 · 7 investors · PharmaceuticalsRule 506(c)
▶$3.4MraisedFeb 2015 · 7 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Mary KatofiascPromoter
- Tatyana TouzovaPromoter
- Karl B ThorExecutive Officer, Director, Promoter
- Edward C BurgardExecutive Officer, Director, Promoter
- Benny WardExecutive Officer, Director, Promoter
- Daniel J RiccaDirector, Promoter
- Ebrahim VersiDirector, Promoter
- Florenta Aura KullmannPromoter
- Fred EshelmanDirector
- Venkateswarlu KarichetiPromoter
- Lesley MarsonPromoter
- Offering amount
- $3.4M
- Amount sold
- $3.4M
- Minimum investment
- $100K
- Proceeds to insiders
- $1M
- First sale
- Oct 2014
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
IndustriesJ.P. Morgan is a global financial services firm serving corporations and individuals in more than 100 countries, offering investment research, tools, data, analytics, and advisory services. It supports institutional investors, asset and fund managers, hedge funds, broker dealers, and equity issuers with liquidity, fixed income strategies, and equity compensation solutions.
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
ForbionA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.
Mmm OnlineCore-Rx is an independent agency that provides pharmaceutical and healthcare marketing services, including campaign development, creative direction, and digital innovation. The agency serves pharmaceutical and biotech companies with strategic marketing, content creation, and technology integration services.
Syneos HealthSyneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
Companies working in the same space as Dignify Therapeutics.
Non-dilutive funding · 18 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $541.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $394.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $244.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $901.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $269.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $275.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $199.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $159.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Dignify Therapeutics do?
- Dignify Therapeutics is developing drug programs that induce on-demand defecation and urination to treat functional bowel and bladder disorders, including incontinence and retention associated with neurological conditions and aging. Its candidates are intended to reduce reliance on bladder catheters, manual bowel programs, and adult wearables, and to lower the risk of related infections and hospitalization.
- Who founded Dignify Therapeutics?
- Dignify Therapeutics was founded by Edward C Burgard, Karl Thor in 2013.
- Who are Dignify Therapeutics's investors?
- Dignify Therapeutics's investors include Eshelman Ventures, LLC, RA Capital, Montreux Equity Partners.
- How much funding has Dignify Therapeutics raised?
- Dignify Therapeutics has disclosed $4.2M raised across 2 rounds.
- Where is Dignify Therapeutics headquartered?
- Dignify Therapeutics is headquartered in Research Triangle Park, US.